Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 15/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PKLR | P30613 | 1/20 | 0.47 |
| ▸ | PDE1A | P54750 | 2/20 | 0.47 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.47 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27077835 | 0.91 | NPBWR1 (0.54) | NPBWR1MCHR1AURKAAURKBPKM | |
| SCHEMBL27077803 | 0.83 | NPBWR1 (0.56) | NPBWR1MCHR1AURKAAURKBPKM | |
| SCHEMBL27435547 | 0.82 | NPBWR1 (0.53) | NPBWR1MCHR1AURKAAURKBPKM | |
| SCHEMBL30579886 | 0.79 | TDP1 (0.64) | NPBWR1MCHR1PKMCASP3 | |
| SCHEMBL27077642 | 0.78 | NPBWR1 (0.49) | NPBWR1MCHR1AURKAAURKBPKM | |
| SCHEMBL25431853 | 0.77 | NPBWR1 (0.52) | NPBWR1MCHR1PKMPKLRPDE1A | |
| SCHEMBL16131523 | 0.75 | NPBWR1 (0.47) | NPBWR1MCHR1AURKAAURKBPKM | |
| SCHEMBL16131528 | 0.74 | MEN1 (0.51) | NPBWR1MCHR1AURKAAURKBPKM | |
| SCHEMBL27077660 | 0.74 | NPBWR1 (0.57) | NPBWR1MCHR1PKMPKLRPDE1A | |
| SCHEMBL27077873 | 0.73 | NPBWR1 (0.59) | NPBWR1MCHR1AURKAAURKBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-07-04 | — | — | US | disclosed |
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-07-04 | — | — | US | disclosed |
| EP-4313300-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| CN-117460723-A | Pharmaceutical compounds | 杜克街生物有限公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2022207752-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | F11, F12, ZYX | NPBWR1 830/4885MCHR1 1306/4885AURKA 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.